What to Expect This Flu Season
Experts say it could be a bad year, but North Carolina’s weather could help slow the spread.
Tag: Infectious Diseases
‘To seek a true cure’: UNC researchers pioneer HIV research w...
In honor of World AIDS Day on Dec. 1, we take a look at the trailblazing ‘kick and kill’ method of attacking HIV to cure patients. UNC researchers have been working with GlaxoSmithKline on parallel studies at the UNC Cure Center for 18 months to advance this new method of combating the global epidemic of HIV.
UNC researchers find that Malaria parasite evades rapid test detect...
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Can nanotechnology help develop a workable dengue virus vaccine?
UNC School of Medicine researchers Aravinda de Silva, PhD, professor of microbiology and immunology, and Stefan Metz, PhD, are creating a nanoparticle vaccine that in experiments showed increased antibody responses against one serotype of dengue virus. The de Silva group is collaborating with the UNC laboratories of Chris Luft, PhD, (pharmacy and chemistry), Jenny Ting, PhD, (genetics), and Mike Miley,PhD, (pharmacology), as well as Liquidia Pharmaceuticals to use the same nanoparticle platform to develop a vaccine for all four serotypes of the virus.
UNC scientists named to European Union-funded global Zika research ...
The UNC School of Medicine was one of two U.S. institutions named to an international research consortium funded through the European Union’s Horizon 2020 Programme, which invested $49 million in Zika research and vaccine development at more than 20 laboratories in Europe and Brazil.
Weber delivers Zika, travel update to UNC School of Medicine faculty
David Weber, MD, MPH, Matt Collins, MD, PhD, and Helen Lazear, PhD, were the featured speakers addressing the Zika virus epidemic during lecture at the UNC School of Medicine.
Tuberculosis screening, isoniazid preventative therapy reduce morta...
The study published in The Lancet showed no therapeutic benefit of empiric TB therapy for patients with HIV.
